198 completed. 198 Phase 3, 35 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 198 | Completed 198 |
| Phase 2 | 35 | Completed 35 |
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMX0035 and Progressive Supranuclear Palsy AMX0035, Placebo - Progressive Supranuclear Palsy, PSP | Phase 2 / Phase 3 | Completed | Amylyx Pharmaceuticals Inc. | 139 | 2023-12-21 | 2026-04-30 |
| Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care - Mild Cognitive Impairment, Dementia, Mild | Phase 3 | Completed | Alzheimer's Prevention and Reversal Project, Inc. | 73 | 2023-07-31 | 2026-02-18 |
| A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease Semaglutide, Placebo - Alzheimers Disease | Phase 3 | Completed | Novo Nordisk A/S | 23 | 2023-06-20 | 2026-08-18 |
| A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD Buntanetap/Posiphen, Placebo - Alzheimer Disease | Phase 2 / Phase 3 | Completed | Annovis Bio Inc. | 351 | 2023-04-01 | 2025-04-29 |
| A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation AXS-05, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Completed | Axsome Therapeutics, Inc. | 408 | 2022-09-06 | 2026-08-13 |
| A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) Remternetug (IV), Remternetug (SC), Placebo - Alzheimer's Disease | Phase 3 | Completed | Eli Lilly and Company | 1667 | 2022-08-01 | 2026-05-22 |
| [18F]APN-1607 PET in Subjects With AD Compared to HC [18F]APN-1607 - Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease | Phase 3 | Completed | APRINOIA Therapeutics | 230 | 2022-01-21 | 2025-09-08 |
| A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) Donanemab, Aducanumab - Mild Cognitive Impairment (MCI), Alzheimer Disease | Phase 3 | Completed | Eli Lilly and Company | 148 | 2021-11-16 | 2024-11-29 |
| Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease Simufilam, Placebo - Alzheimer Disease | Phase 3 | Completed | Cassava Sciences, Inc. | 804 | 2021-11-03 | 2025-05-25 |
| A Phase 3 Study of NE3107 in Probable Alzheimer's Disease NE3107, Placebo - Alzheimer Disease | Phase 3 | Completed | BioVie Inc. | 439 | 2021-08-05 | 2023-11-21 |
| Effect of Hydralazine on Alzheimer's Disease Hydralazine hydrochloride 25mg tablets, Placebo - Alzheimer Disease | Phase 3 | Completed | Shahid Sadoughi University of Medical Sciences and Health Services | 228 | 2021-08-02 | 2026-09-09 |
| A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation AXS-05 (dextromethorphan-bupropion), Placebo - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Completed | Axsome Therapeutics, Inc. | 456 | 2021-06-17 | 2025-12-08 |
| An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects Experimental: ALZ-801, Placebo Comparator: Placebo - Early Alzheimer's Disease | Phase 3 | Completed | Alzheon Inc. | 325 | 2021-05-19 | 2026-09-29 |
| A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Semagludtide, Placebo (semaglutide) - Early Alzheimer's Disease | Phase 3 | Completed | Novo Nordisk A/S | 1840 | 2021-05-18 | 2026-07-07 |
| Assessing Clinical Outcomes in Alzheimer's Disease Agitation AXS-05, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Completed | Axsome Therapeutics, Inc. | 178 | 2020-12-31 | 2023-11-29 |
| ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease ATH-1017, Placebo - Alzheimer Disease, Dementia of Alzheimer Type | Phase 2 / Phase 3 | Completed | LeonaBio | 554 | 2020-09-28 | 2025-04-04 |
| A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients DaTSCAN™ Ioflupane (123I) Injection - Parkinsonian Syndrome, Parkinson Disease(PD) | Phase 3 | Completed | GE Healthcare | 172 | 2020-06-28 | 2023-10-16 |
| OLE of Phase 2b/3 Study ANAVEX2-73-AD-004 ANAVEX2-73 - Alzheimer Disease | Phase 2 / Phase 3 | Completed | Anavex Life Sciences Corp. | 300 | 2019-10-10 | 2024-08-12 |
| Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease flortaucipir F18, Brain PET Scan - Alzheimer Disease | Phase 3 | Completed | Avid Radiopharmaceuticals | 205 | 2019-03-28 | 2020-08-28 |
| GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease COR388 capsule, Placebo capsule - Alzheimer Disease | Phase 2 / Phase 3 | Completed | Cortexyme Inc. | 643 | 2019-03-28 | 2023-02-23 |
Showing 20 of 198. Sign in to see all of them.
Alzheimer Disease (193) · Dementia (59) · Cognitive Dysfunction (25) · Psychomotor Agitation (19) · Memory Disorders (16) · Brain Diseases (10) · Neurodegenerative Diseases (9) · Dementia, Vascular (8) · Mental Disorders (8) · Amyloid Neuropathies, Familial (6) · Nervous System Diseases (6) · Supranuclear Palsy, Progressive (6) · Amyloidosis (5) · Cognition Disorders (4) · Mixed Dementias (4)
Central Nervous System Diseases (196) · Nervous System Diseases (192) · Neurocognitive Disorders (192) · Neurodegenerative Diseases (189) · Brain Diseases (188) · Mental Disorders (185) · Dementia (134) · Pathological Conditions, Signs and Symptoms (59) · Neurologic Manifestations (51) · Signs and Symptoms (50) · Neurobehavioral Manifestations (42) · Behavior (28) · Cognition Disorders (24) · Behavioral Symptoms (22)
Galantamine (18) · Donepezil (11) · Memantine (8) · Rivastigmine (7) · florbetapir (6) · flutemetamol (6) · (2-(6-fluoro-1H-indol-3-yl)-ethyl)-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)amine (4) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (4) · Aripiprazole (4) · Risperidone (4) · brexpiprazole (4) · tafamidis (4) · N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide (3) · Vitamin E (3) · gantenerumab (3)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (13) · Otsuka Pharmaceutical Development & Commercialization, Inc. (10) · National Institute on Aging (NIA) (9) · Avid Radiopharmaceuticals (8) · Eli Lilly and Company (8) · Pfizer (7) · GE Healthcare (6) · Novartis Pharmaceuticals (5) · Axsome Therapeutics, Inc. (4) · H. Lundbeck A/S (4) · Eisai Inc. (3) · Forest Laboratories (3) · Novartis (3) · TauRx Therapeutics Ltd (3) · US Department of Veterans Affairs (3)
United States (128) · Canada (46) · France (40) · Germany (38) · United Kingdom (35) · Spain (32) · Australia (28) · Italy (28) · Poland (21) · South Korea (19) · Sweden (18) · Czechia (16) · Japan (16) · Brazil (15) · Netherlands (15)
Leon Thal, MD. (3) · Mary Sano, PhD (3) · Jacobo Mintzer, MD (2) · Jane Yardley, Ph.D (2)
PMID 39498781, PMID 39800465, PMID 26120369, PMID 26402769, PMID 40681915, PMID 41533472, PMID 41961243, PMID 29318278, PMID 30474567, PMID 31193334, PMID 33189083, PMID 39108660, PMID 41591746, PMID 20921879, PMID 22749065, PMID 24450890, PMID 24450891, PMID 25125457, PMID 26208959, PMID 27494299, PMID 28269765, PMID 29615123, PMID 29854934, PMID 29854935, PMID 30412493, PMID 30558645, PMID 31353964, PMID 31708380, PMID 31831056, PMID 32107748, PMID 32524297, PMID 33070419, PMID 33587110, PMID 34923848, PMID 36627206, PMID 36715498, PMID 36946603, PMID 37434378, PMID 37943223, PMID 38932583, PMID 39177596, PMID 40488446, PMID 40603145, PMID 40847656, PMID 41439450, PMID 41689409, PMID 42052145, PMID 42502037, PMID 42658466, PMID 10084637
U01AG010483 (5), 2016 (3), 1RC2AG036535 (2), 2017 (2), 2023 (2), 2009 (1), 2015 (1), 2018 (1), F32MH075583 (1), I01RX001507 (1), R01AG016381 (1), R01AG017196 (1), R01AG027156 (1), R01AG029624 (1), R01AG031348 (1)